Clinical Trials in San Diego

Showing 1961-1980 of 7,028 trials

Open-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome

NCT05701774

The purpose of this is study is to evaluate the long-term safety of DCCR (diazoxide choline) extended-release tablets) in patients with Prader-Willi syndrome.

Prader-Willi Syndrome

Soleno Therapeutics, Inc.83 participantsStarted Jan 2023

Orange, California, United States • Palo Alto, California, United States • San Diego, California, United States +19 more locations

Active Not RecruitingPhase 1/2< 1 mile

Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)

NCT05747924

A Randomized, Double-blind, Placebo-controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of AOC 1020 Administered Intravenously to Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)

FSHDFSHD1FSHD2+24 more

Avidity Biosciences, Inc.90 participantsStarted Apr 2023

Los Angeles, California, United States • Palo Alto, California, United States • San Diego, California, United States +14 more locations

Open-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome

Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)

Find Trials by Condition in San Diego

A Study to Evaluate Whether Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease

MIP Versus PCNL for Kidney Stone Disease

Detection and Classification of Cardiac Rhythm and Atrial Fibrillation Using a Finger-worn Ring

MyMenoPlan: Online Resource for Improving Women's Menopause Knowledge and Informed Decision-making

Incentive Processing and Learning in Anorexia Nervosa and Bulimia Nervosa

Envi™-SR Randomized Controlled Trial for Endovascular Treatment of Ischemic Stroke

A Bioequivalence Study of Mirikizumab (LY3074828) Solution in Healthy Participants

Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma

Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab

Study of Once-Daily Oral RGT001-075 Compared With Placebo in Adults With Obesity or Are Overweight With Weight-Related Health Conditions

Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer

Pharmacokinetic, Pharmacodynamic, Safety, and Efficacy Study of Rivaroxaban for Thromboprophylaxis in Pediatric Participants 2 to 8 Years of Age After the Fontan Procedure

Clinical Study Assessing the Efficacy and Safety of Macitentan in Fontan-palliated Subjects

A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment

Quality Improvement and Clinical Utility PrecivityAD2(TM) Clinician Survey

A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults

The DETOUR 2 Clinical Trial

Outcome of Patients with Severe Functional TR According to Medical, Transcatheter or Surgical Treatment